Second-Generation vs. First-Generation Drug-Eluting Stents in Patients With Calcified Coronary Lesions - Pooled Analysis From the RESET and NEXT Trials

Circ J. 2018 Jan 25;82(2):376-387. doi: 10.1253/circj.CJ-17-0746. Epub 2017 Oct 5.

Abstract

Background: The comparative efficacy of second-generation (G2) vs. first-generation (G1) drug-eluting stents (DES) for calcified coronary lesions is unknown.Methods and Results:We compared the 3-year clinical outcomes of patients with G1- or G2-DES according to the presence or absence of calcified coronary lesions as assessed in an angiographic core laboratory using data from 2 large-scale prospective multicenter randomized trials, RESET and NEXT. G1-DES and G2-DES were implanted in 299 and 1,033 patients, respectively, in the Calc stratum (≥1 lesion with moderate/severe calcification), and 1,208 and 3,550 patients, respectively, in the Non-calc stratum (no/mild calcification). The patients in the Calc stratum had a significantly higher adjusted risk for the primary outcome measure (any target-lesion revascularization (TLR)) than those in the Non-calc stratum (HR: 1.38, 95% CI: 1.11-1.71, P=0.004). The cumulative 3-year incidence of any TLR was not significantly different between the G1-DES and G2-DES groups in both the Calc and Non-calc strata (12.1% vs. 9.7%, P=0.22, and 6.8% vs. 6.1%, P=0.44, respectively). After adjusting for confounders, the effect of G2DES relative to G1-DES for any TLR remained insignificant in both the Calc and Non-calc strata (HR: 0.78, 95% CI: 0.48-1.25, P=0.3, and HR: 0.84, 95% CI: 0.61-1.17, P=0.31, respectively, P interaction=0.55).

Conclusions: The effect of G2-DES relative to G1-DES for TLR was not significantly different regardless of the presence or absence of lesion calcification.

Keywords: Coronary artery calcification; Percutaneous coronary intervention; Second-generation drug-eluting stents.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Calcinosis / therapy*
  • Coronary Artery Disease / therapy*
  • Drug-Eluting Stents / standards*
  • Everolimus / administration & dosage
  • Female
  • Humans
  • Immunosuppressive Agents
  • Male
  • Middle Aged
  • Myocardial Revascularization / standards
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Everolimus
  • umirolimus
  • Sirolimus